Fiche du document
12 janvier 2021
- doi: 10.3390/ncrna7010005
- issn: 2311-553X
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.3390/ncrna7010005
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/33445472
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/eissn/2311-553X
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_624A54C72BF42
info:eu-repo/semantics/openAccess , CC BY 4.0 , https://creativecommons.org/licenses/by/4.0/
Sujets proches
Melanocytic tumor Malignant melanomaCiter ce document
M. Tusup et al., « Evaluation of the Interplay between the ADAR Editome and Immunotherapy in Melanoma. », Serveur académique Lausannois, ID : 10.3390/ncrna7010005
Métriques
Partage / Export
Résumé
RNA editing is a highly conserved posttranscriptional mechanism that contributes to transcriptome diversity. In mammals, it includes nucleobase deaminations that convert cytidine (C) into uridine (U) and adenosine (A) into inosine (I). Evidence from cancer studies indicates that RNA-editing enzymes promote certain mechanisms of tumorigenesis. On the other hand, recoding editing in mRNA can generate mutations in proteins that can participate in the Major Histocompatibility Complex (MHC) ligandome and can therefore be recognized by the adaptive immune system. Anti-cancer treatment based on the administration of immune checkpoint inhibitors enhance these natural anti-cancer immune responses. Based on RNA-Seq datasets, we evaluated the editome of melanoma cell lines generated from patients pre- and post-immunotherapy with immune checkpoint inhibitors. Our results reveal a differential editing in Arthrobacter luteus (Alu) sequences between samples pre-therapy and relapses during therapy with immune checkpoint inhibitors. These data pave the way towards the development of new diagnostics and therapies targeted to editing that could help in preventing relapses during immunotherapies.